Latest Immunosuppressants Stories
EXTON, Pa., March 5, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, although there have been no significant changes with regard to biologic treatment and Crohn's disease (CD) patients with active disease since 2012, surveyed gastroenterologist data indicate a significant 43 percent increase in biologic treatment among CD patients in remission since 2012, suggesting that...
Phase 1b Data Presented at Late Breaking Session of 71st Annual Meeting of the American Academy of Dermatology PARIS and TARRYTOWN, N.Y., March 2, 2013 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that pooled data from two Phase 1b trials with dupilumab (REGN668/SAR231893), an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting the alpha subunit of the interleukin 4...
Steroids do not prevent this antibody-mediated injury and rejection Highlights: -Pediatric kidney transplant recipients who have antibodies directed against their new organ are more likely to experience kidney injury and rejection than patients without these antibodies. -Steroids do not prevent this antibody-mediated injury and rejection. -Approximately 2,500 children received a kidney transplant last year in the United States. A transplanted kidney has a finite life expectancy...
LONDON, February 22, 2013 /PRNewswire/ -- Biotech sector has a promising future. With the rise in occupational and lifestyle ailments, the demand for biotech products is expected to rise. Increased age expectancy is another major factor behind the growth of the sector. However, biotech companies work in an uncertain environment and the fortunes of a company may make or break with a single FDA decision. Ariad Pharmaceuticals Inc. (NASDAQ: ARIA) recently received approval for...
ATLANTA, Feb. 20, 2013 /PRNewswire/ -- UCB announced today two new regulatory filings with the US Food and Drug Administration (FDA) and with the European Medicines Agency (EMA) to extend the marketing authorization for Cimzia(®) (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA) and for adult patients with active axial spondyloarthritis (axSpA). The regulatory filings for two new indications for certolizumab pegol are now under review...
EAST HANOVER, N.J., Feb. 15, 2013 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) has approved Zortress(®) (everolimus) for the prophylaxis of organ rejection in adult patients receiving a liver transplant. Zortress is the first mammalian target of rapamycin (mTOR) inhibitor approved for use following liver transplantation. It is also the first immunosuppressant approved by the FDA in over a decade for use following liver...
The Newly-Released Award-Winning Movie Burzynski Documenting the U.S. Patent Office’s Alleged Collusion with the FDA to Enrich Big Pharma by Denying Americans Access to Life-Saving Cancer Treatments Inspires Neurological Wellness Center Physicians to Decry a Similar Move by the U.S. Patent Office, FDA and Big Pharma to Deny Americans Access to Effective Alzheimer’s Treatment, Stroke Treatment and Traumatic Brain Injury Treatment. (PRWEB) February 13, 2013 Unlike Dr. Burzenski’s...
NATICK, Mass., Feb. 12, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the Promus PREMIER(TM) Everolimus-Eluting Platinum Chromium Coronary Stent System, the company's next-generation durable polymer drug-eluting stent (DES) technology, and is starting its European market launch. The Promus PREMIER Stent System is designed to provide physicians improved DES performance in treating patients with coronary artery disease. It is the...
SINGAPORE, Feb. 7, 2013 /PRNewswire/ -- Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices, has announced a collaboration with Terumo Corporation to promote the Nobori(TM) drug-eluting stent (DES) system at specific specialist cardiology centers in Japan. Nobori incorporates two elements of Biosensors-developed technology: Biolimus A9(TM)...
A newly released study involving 629 patients has inspired Neurological Wellness Center physicians to lament that the lives of millions would be meaningfully ameliorated if perispinal Enbrel treatments were routinely administered. The continued off-label status of perispinal Enbrel serves to limit access to all but the well-connected, medically savvy consumer. (PRWEB) February 06, 2013 The growing body of published observational data showing significant and rapid improvement in physical...
